Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database

ObjectiveTreatment options with disease-modifying antirheumatic drugs (DMARDs) for psoriatic arthritis (PsA) have evolved over recent years. In addition to Janus kinase inhibitors (JAKi), four classes of biologic DMARDs (bDMARDs; interleukin [IL]-23 inhibitors [IL-23i], IL-12/23 inhibitors [IL-12/23...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Patrick-Pascal Strunz, Matthias Englbrecht, Linus Maximilian Risser, Torsten Witte, Matthias Froehlich, Marc Schmalzing, Michael Gernert, Astrid Schmieder, Peter Bartz-Bazzanella, Cay von der Decken, Kirsten Karberg, Georg Gauler, Patrick Wurth, Susanna Späthling-Mestekemper, Christoph Kuhn, Wolfgang Vorbrüggen, Johannes Heck, Martin Welcker, Stefan Kleinert
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Frontiers Media S.A. 2024-05-01
Seri Bilgileri:	Frontiers in Immunology
Konular:	treatment persistence tofacitinib upadacitinib ustekinumab real-world biologics
Online Erişim:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1395968/full
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!